Comparison of patient preference for sensory attributes of fluticasone furoate or
fluticasone propionate in adults with seasonal allergic rhinitis: a randomized,
placebo-controlled, double-blind study.
Author(s): Meltzer EO, Andrews C, Journeay GE, Lim J, Prillaman BA, Garris C, Philpot E.
Affiliation(s): Allergy and Asthma Medical Group and Research Center, San Diego, California
92123, USA. eomeltzer@aol.com
Publication date & source: 2010, Ann Allergy Asthma Immunol. , 104(4):331-8
BACKGROUND: Intranasal corticosteroids are first-line treatment for
moderate-to-severe seasonal allergic rhinitis (AR).
OBJECTIVES: To compare preferences for fluticasone furoate and fluticasone
propionate nasal sprays after 1 week of treatment in patients with symptomatic
seasonal AR.
METHODS: Patients with seasonal AR were enrolled (n = 360) and randomized 1:1 to
active treatment (fluticasone furoate, 110 microg, or fluticasone propionate, 200
microg, followed by crossover treatment for 1 week each) or matched placebo
sequence with a 1-week washout before crossover dosing. Fluticasone furoate and
fluticasone propionate efficacy was measured by change from baseline during 1
week in daily reflective total nasal symptom score (rTNSS) that assessed severity
of rhinorrhea, nasal congestion, nasal itching, and sneezing. Patient preference
for fluticasone furoate or fluticasone propionate was assessed at the end of the
study by questionnaire.
RESULTS: Three hundred sixty patients from 29 clinical sites in the Unites States
were randomized and treated between August 1, 2007 and November 30, 2007. Most
patients were white (73%) and female (59%), with a mean age of 38.3 years, and
had had seasonal AR for at least 10 years (74%). Fluticasone furoate and
fluticasone propionate each reduced the daily rTNSS compared with their
respective placebos (least squares mean [SD] difference, -0.8 [0.24], P < .001,
and -0.6 [0.24], P = .01, respectively). More patients (P < .001) preferred
fluticasone furoate to fluticasone propionate based on attributes of scent or
odor (58% vs 27%), aftertaste (60% vs 18%), leaking out of the nose and down the
throat (59% vs 21%), and mist gentleness (57% vs 26%). No statistically
significant differences were seen in preferences regarding ease of use, delivery
method, or device comfort.
CONCLUSION: Both fluticasone furoate and fluticasone propionate significantly
improved symptoms in adult patients with seasonal AR. Most patients preferred the
sensory attributes of fluticasone furoate to those of fluticasone propionate
after 1 week of treatment.
|
